Patents by Inventor Cesar M. Compadre

Cesar M. Compadre has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210332062
    Abstract: The present disclosure provides SL and SL derivatives comprising a polar substituent adjacent to the lactone ring. Additionally, the present disclosure provides methods of using the SL and SL derivatives to inhibit the growth of leukemic cancer cells.
    Type: Application
    Filed: May 28, 2021
    Publication date: October 28, 2021
    Applicant: Board of Trustees of the University of Arkansas
    Inventors: Monica L. Guzman, Cesar M. Compadre, Paola E. Ordonez, Mariano Martinez, Michael J. Balick, Darin E. Jones, Flavio G. Gaudio
  • Patent number: 11116746
    Abstract: Provided herein is a tocol rich fraction of rice bran oil deodorized distillate that is shown to be both radioprotective and able to protect against oxidative damage. This fraction may prove an inexpensive and readily available extract that can be used to prepare pharmaceutical compositions for use in protecting against radiation exposure and/or other forms of oxidative stress.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: September 14, 2021
    Assignee: Tocol Pharmaceuticals, LLC
    Inventors: Cesar M. Compadre, Philip Breen, Nukhet Aykin-Burns, Martin Hauer-Jensen
  • Patent number: 11059800
    Abstract: The present invention provides dehydroleucodine derivatives. In particular, the present invention provides amine derivatives of dehydroleucodine and methods of using dehydroleucodine and the amine derivatives of dehydroleucodine to inhibit the growth of cancer cells.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: July 13, 2021
    Assignees: Universidad Tecnica Particular De Loja, Cornell University, BioVentures, LLC
    Inventors: Cesar M. Compadre, Paola E. Ordonez, Monica L. Guzman, Darin E. Jones, Omar Malagon, Giovanni Vidari, Peter Crooks
  • Patent number: 11021488
    Abstract: The present disclosure provides SL and SL derivatives comprising a polar substituent adjacent to the lactone ring. Additionally, the present disclosure provides methods of using the SL and SL derivatives to inhibit the growth of leukemic cancer cells.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: June 1, 2021
    Assignees: Board of Trustees of the University of Arkansas, BioVentures, LLC, Cornell University, New York Botanical Garden
    Inventors: Monica L. Guzman, Cesar M. Compadre, Paola E. Ordonez, Mariano Martinez, Michael J. Balick, Darin E. Jones, Flavio G. Gaudio
  • Publication number: 20190345167
    Abstract: The present disclosure provides SL and SL derivatives comprising a polar substituent adjacent to the lactone ring. Additionally, the present disclosure provides methods of using the SL and SL derivatives to inhibit the growth of leukemic cancer cells.
    Type: Application
    Filed: July 26, 2019
    Publication date: November 14, 2019
    Applicant: Board of Trustees of the University of Arkansas
    Inventors: Monica L. Guzman, Cesar M. Compadre, Paola E. Ordonez, Mariano Martinez, Michael J. Balick, Darin E. Jones, Flavio G. Gaudio
  • Patent number: 10357474
    Abstract: Plant extracts, compositions, pharmaceutical compositions and methods of making and using the same are provided herein. The compositions comprise ?-tocotrienol (GT3) and ?-tocotrienol (DT3) in ratios wherein the DT3 is predominate. The compositions are useful for radioprotection and radiomitigation in subjects in need thereof.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: July 23, 2019
    Assignees: BIOVENTURES, LLC, UNIVERSIDAD TECNICA PARTICULAR DE LOJA, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Cesar M. Compadre, Philip Breen, Nukhet Aykin-Burns, Martin Hauer-Jensen, Raul G. Enriquez, Sujay Kharade, Omar Malagon, Yadira Ordonez, Edgar Ojeda, Shraddha Thakkar, E. Nathalie Pineda, Darin Jones
  • Publication number: 20190185442
    Abstract: The present invention provides dehydroleucodine derivatives. In particular, the present invention provides amine derivatives of dehydroleucodine and methods of using dehydroleucodine and the amine derivatives of dehydroleucodine to inhibit the growth of cancer cells.
    Type: Application
    Filed: February 22, 2019
    Publication date: June 20, 2019
    Inventors: Cesar M. Compadre, Paola E. Ordonez, Monica L. Guzman, Darin E. Jones, Omar Malagon, Giovanni Vidari, Peter Crooks
  • Publication number: 20190142791
    Abstract: Provided herein is a tocol rich fraction of rice bran oil deodorized distillate that is shown to be both radioprotective and able to protect against oxidative damage. This fraction may prove an inexpensive and readily available extract that can be used to prepare pharmaceutical compositions for use in protecting against radiation exposure and/or other forms of oxidative stress.
    Type: Application
    Filed: January 11, 2019
    Publication date: May 16, 2019
    Applicant: Tocol Pharmaceuticals, LLC
    Inventors: Cesar M. Compadre, Philip Breen, Nukhet Aykin-Burns, Martin Hauer-Jensen
  • Publication number: 20180319815
    Abstract: The present disclosure provides SL and SL derivatives comprising a polar substituent adjacent to the lactone ring. Additionally, the present disclosure provides methods of using the SL and SL derivatives to inhibit the growth of leukemic cancer cells.
    Type: Application
    Filed: November 3, 2016
    Publication date: November 8, 2018
    Applicant: Board of Trustees of the University of Arkansas
    Inventors: Monica L. Guzman, Cesar M. Compadre, Paola E. Ordonez, Mariano Martinez, Michael J. Balick, Darin E. Jones, Flavio G. Gaudio
  • Publication number: 20180271829
    Abstract: Plant extracts, compositions, pharmaceutical compositions and methods of making and using the same are provided herein. The compositions comprise ?-tocotrienol (GT3) and ?-tocotrienol (DT3) in ratios wherein the DT3 is predominate. The compositions are useful for radioprotection and radiomitigation in subjects in need thereof.
    Type: Application
    Filed: June 1, 2018
    Publication date: September 27, 2018
    Applicants: BioVentures, LLC, Universidad Tecnica Particular De Loja, The United States of America as Represented by the Department of Veterans Affairs
    Inventors: Cesar M. Compadre, Philip Breen, Nukhet Aykin-Burns, Martin Hauer-Jensen, Raul G. Enriquez, Sujay Kharade, Omar Malagon, Yadira Ordonez, Edgar Ojeda, Shraddha Thakkar, E. Nathalie Pineda, Darin Jones
  • Patent number: 9993456
    Abstract: Plant extracts, compositions, pharmaceutical compositions and methods of making and using the same are provided herein. The compositions comprise ?-tocotrienol (GT3) and ?-tocotrienol (DT3) in ratios wherein the DT3 is predominate. The compositions are useful for radioprotection and radiomitigation in subjects in need thereof.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: June 12, 2018
    Assignees: The Board of Trustees of the University of Arkansas, Universidad Tecnica Particular De Loja, The United States of America as Represented by the Department of Veterans Affairs
    Inventors: Cesar M. Compadre, Philip Breen, Nukhet Aykin-Burns, Martin Hauer-Jensen, Raul G. Enriquez, Sujay Kharade, Omar Malagon, Yadira Ordonez, Edgar Ojeda, Shraddha Thakkar, E. Nathalie Pineda, Darin Jones
  • Publication number: 20160324914
    Abstract: Provided herein is a tocol rich fraction of rice bran oil deodorized distillate that is shown to be both radioprotective and able to protect against oxidative damage. This fraction may prove an inexpensive and readily available extract that can be used to prepare pharmaceutical compositions for use in protecting against radiation exposure and/or other forms of oxidative stress.
    Type: Application
    Filed: May 5, 2016
    Publication date: November 10, 2016
    Applicant: TOCOL PHARMACEUTICALS, LLC
    Inventors: Cesar M. Compadre, Philip Breen, Nukhet Aykin-Burns, Martin Hauer-Jensen
  • Publication number: 20160220530
    Abstract: Plant extracts, compositions, pharmaceutical compositions and methods of making and using the same are provided herein. The compositions comprise ?-tocotrienol (GT3) and ?-tocotrienol (DT3) in ratios wherein the DT3 is predominate. The compositions are useful for radioprotection and radiomitigation in subjects in need thereof.
    Type: Application
    Filed: September 15, 2014
    Publication date: August 4, 2016
    Applicants: The Board of Trustees of the University of Arkansas, Universidad Tecnica Particular De Loja, United States Department of Veterans Affairs
    Inventors: Cesar M. Compadre, Philip Breen, Nukhet Aykin-Burns, Martin Hauer-Jensen, Raul G. Enriquez, Sujay Kharade, Omar Malagon, Yadira Ordonez, Edgar Ojeda, Shraddha Thakkar, E. Nathalie Pineda, Darin Jones
  • Publication number: 20160176839
    Abstract: The present invention provides dehydroleucodine derivatives. In particular, the present invention provides amine derivatives of dehydroleucodine and methods of using dehydroleucodine and the amine derivatives of dehydroleucodine to inhibit the growth of cancer cells.
    Type: Application
    Filed: July 11, 2014
    Publication date: June 23, 2016
    Inventors: Cesar M. Compadre, Paola E. Ordonez, Monica L. Guzman, Darin E. Jones, Omar Malagon, Giovanni Vidari, Peter Crooks
  • Patent number: 9351492
    Abstract: The present invention provides polyphenolic compositions derived from a plant that inhibit the formation of a biofilm. Also provided are combinations that comprise at least one phenolic phytochemical and at least one antimicrobial agent that inhibit the growth of an established biofilm. Further, the present invention provides methods for inhibiting the formation and growth of biofilms.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: May 31, 2016
    Assignee: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
    Inventors: Cassandra L. Quave, Mark S. Smeltzer, Cesar M. Compadre, Howard Hendrickson
  • Publication number: 20140271777
    Abstract: The present invention provides polyphenolic compositions derived from a plant that inhibit the formation of a biofilm. Also provided are combinations that comprise at least one phenolic phytochemical and at least one antimicrobial agent that inhibit the growth of an established biofilm. Further, the present invention provides methods for inhibiting the formation and growth of biofilms.
    Type: Application
    Filed: April 2, 2014
    Publication date: September 18, 2014
    Applicant: BOARD OF TRUSTEES UNIVERSITY OF ARKANSAS
    Inventors: Cassandra L. Quave, Mark S. Smeltzer, Cesar M. Compadre, Howard Hendrickson
  • Patent number: 8741855
    Abstract: The present invention provides polyphenolic compositions derived from a plant that inhibit the formation of a biofilm. Also provided are combinations that comprise at least one phenolic phytochemical and at least one antimicrobial agent that inhibit the growth of an established biofilm. Further, the present invention provides methods for inhibiting the formation and growth of biofilms.
    Type: Grant
    Filed: October 6, 2011
    Date of Patent: June 3, 2014
    Assignee: The Board of Trustees of the University of Arkansas
    Inventors: Cassandra L. Quave, Mark S. Smeltzer, Cesar M. Compadre, Howard Hendrickson
  • Publication number: 20120283421
    Abstract: It has been determined that allergens, which are characterized by both humoral (IgE) and cellular (T-cell) binding sites, can be modified to be less allergenic by modifying the IgE binding sites. The IgE binding sites can be converted to non-IgE binding sites by altering as little as a single amino acid within the protein, preferably a hydrophobic residue towards the center of the IgE epitope, to eliminate IgE binding. Additionally or alternatively a modified allergen with reduced IgE binding may be prepared by disrupting one or more of the disulfide bonds that are present in the natural allergen. The disulfide bonds may be disrupted chemically, e.g., by reduction and alkylation or by mutating one or more cysteine residues present in the primary amino acid sequence of the natural allergen. In certain embodiments, modified allergens are prepared by both altering one or more linear IgE epitopes and disrupting one or more disulfide bonds of the natural allergen.
    Type: Application
    Filed: July 15, 2011
    Publication date: November 8, 2012
    Inventors: Michael J. Caplan, Howard B. Sosin, Hugh A. Sampson, Gary A. Bannon, A. Wesley Burks, JR., Gael Cockrell, Cesar M. Compadre, Cathie Connaughton, Ricki M. Helm, Nina E. King, Randall A. Kopper, Soheila J. Maleki, Patrick A. Rabjohn, David S. Shin, J. Steven Stanley
  • Publication number: 20120088671
    Abstract: The present invention provides polyphenolic compositions derived from a plant that inhibit the formation of a biofilm. Also provided are combinations that comprise at least one phenolic phytochemical and at least one antimicrobial agent that inhibit the growth of an established biofilm. Further, the present invention provides methods for inhibiting the formation and growth of biofilms.
    Type: Application
    Filed: October 6, 2011
    Publication date: April 12, 2012
    Applicant: BOARD OF TRUSTEES UNIVERSITY OF ARKANSAS
    Inventors: Cassandra L. Quave, Mark S. Smeltzer, Cesar M. Compadre, Howard Hendrickson
  • Publication number: 20030202980
    Abstract: It has been determined that allergens, which are characterized by both humoral (IgE) and cellular (T-cell) binding sites, can be modified to be less allergenic by modifying the IgE binding sites. The IgE binding sites can be converted to non-IgE binding sites by altering as little as a single amino acid within the protein, preferably a hydrophobic residue towards the center of the IgE epitope, to eliminate IgE binding. Additionally or alternatively a modified allergen with reduced IgE binding may be prepared by disrupting one or more of the disulfide bonds that are present in the natural allergen. The disulfide bonds may be disrupted chemically, e.g., by reduction and alkylation or by mutating one or more cysteine residues present in the primary amino acid sequence of the natural allergen. In certain embodiments, modified allergens are prepared by both altering one or more linear IgE eitopes and disrupting one or more disulfide bonds of the natural allergen.
    Type: Application
    Filed: March 18, 2002
    Publication date: October 30, 2003
    Inventors: Michael J. Caplan, Howard B. Sosin, Hugh Sampson, Gary A. Bannon, A. Wesley Burks, Gael Cockrell, Cesar M. Compadre, Cathie Connaughton, Ricki M. Helm, Nina E. King, Randall A. Kopper, Soheila J. Maleki, Patrick A. Rabjohn, David S. Shin, J. Steven Stanley